LaDora V. Thompson

Altered proteasome structure, function, and oxidation in aged muscle

The proteasome is the main protease for degrading oxidized proteins. We asked whether altered proteasome function contributes to the accumulation of oxidized muscle proteins with aging. Proteasome structure, function, and oxidation state were compared in young and aged F344BN rat fast‐twitch skeletal muscle. In proteasome‐enriched homogenates from aged muscle, we observed a two‐ to threefold increase in content of the 20S proteasome that was due to a corresponding increase in immunoproteasome. Content of the regulatory proteins, PA700 and PA28, relative to the 20S were reduced 75% with aging. Upon addition of exogenous PA700, there was a twofold increase in peptide hydrolysis in aged muscle, suggesting the endogenous content of PA700 is inadequate for complete activation of the 20S. Measures of catalytic activity showed a 50% reduction in specific activity for proteasome‐enriched homogenates with aging. With purification of the 20S, proteasome specific activity was equivalent between ages, indicating that endogenous regulators inhibit proteasome in aged muscle. Significantly less degradation of oxidized calmodulin by the 20S from aged muscle was observed. Partial rescue of activity for aged 20S by DTT implies oxidation of functionally significant cysteines. These results demonstrate significant age‐related changes in proteasome structure, function, and oxidation state that could inhibit removal of oxidized proteins.

Age-related muscle dysfunction

Aging is associated with a progressive decline of muscle mass, strength, and quality, a condition described as sarcopenia of aging. Despite the significance of skeletal muscle atrophy, the mechanisms responsible for the deterioration of muscle performance are only partially understood. The purpose of this review is to highlight cellular, molecular, and biochemical changes that contribute to age-related muscle dysfunction.

Influence of simulated bed rest and intermittent weight bearing on single skeletal muscle fiber function in aged rats

OBJECTIVE To characterize specific musculoskeletal contractile property changes that occur during inactivity and intermittent weight bearing in aged muscle. DESIGN Randomized control trial. SETTING A controlled laboratory environment. SUBJECTS Fifteen aged rats were randomly assigned to control (CON), hindlimb unweighted (HU), and hindlimb unweighted with intermittent weight bearing (HU-IWB) groups. INTERVENTIONS The HU and HU-IWB rats were suspended for 1 week. The HU-IWB animals were unsuspended four times daily allowing 15 minutes of weight-bearing. MAIN OUTCOME MEASURES Muscle weights, muscle fiber diameter, peak absolute force, peak specific tension (P0), and maximal shortening velocity (V0). RESULTS In comparison to CON animals, the soleus (SOL) wet weight was significantly (p < or = .05) reduced by 19% and 6% in HU and HU-IWB animals, respectively. SOL single fiber analysis showed no difference in fiber diameter between the three groups. However, peak absolute force and P0 of SOL type I fibers were significantly (p < or = .05) reduced in the HU group compared to CON values. V0 of SOL fibers increased with HU. In comparison to CON animals, the gastrocnemius (GAS) wet weight was significantly reduced by 9% and 8% in HU and HU-IWB animals, respectively. CONCLUSIONS Inactivity significantly altered the contractile properties of single fibers isolated from aged mammalian SOL skeletal muscle. Furthermore, minimal weight bearing attenuated these detrimental effects induced by inactivity in the SOL. However, this weight-bearing protocol did not attenuate the inactivity-induced alterations in aged mammalian GAS skeletal muscle.

Clinically Relevant Frailty Index for Mice

Frailty is a clinical syndrome associated with the aging process and adverse outcomes. The purpose of this short report was to initiate the development of a Frailty Index in 27- to 28-month-old C57BL/6 mice that matched the clinical criteria used in humans (weakness, slow walking speed, low activity level, poor endurance). The selected criteria included grip strength, walking speed, physical activity, and endurance. The criteria in mice were evaluated by the inverted-cling grip test, rotarod test, voluntary wheel running, and derived endurance scores. Each criterion had a designated cutoff point (1.5 SD below the cohort mean) to identify the mice with the lowest performance. If a mouse presented with three of the criteria scores below the cutoff points, it was identified as frail. Mild frailty was designated if two criteria were below the cutoff points. In this mouse cohort, one mouse was identified as frail and one was mildly frail. This prevalence of 9% frailty is consistent with the prevalence of frailty in humans at the same survival age. Collectively, our selected criterion, cutoff point, and Frailty Index provide a potential standardized definition for frailty in mice that is consistent with the operational definition of frailty in humans.

Contribution of oxidative stress to pathology in diaphragm and limb muscles with Duchenne muscular dystrophy

Duchenne muscular dystrophy (DMD) is a degenerative skeletal muscle disease that makes walking and breathing difficult. DMD is caused by an X-linked (Xp21) mutation in the dystrophin gene. Dystrophin is a scaffolding protein located in the sarcolemmal cytoskeleton, important in maintaining structural integrity and regulating muscle cell (muscle fiber) growth and repair. Dystrophin deficiency in mouse models (e.g., mdx mouse) destabilizes the interface between muscle fibers and the extracellular matrix, resulting in profound damage, inflammation, and weakness in diaphragm and limb muscles. While the link between dystrophin deficiency with inflammation and pathology is multi-factorial, elevated oxidative stress has been proposed as a central mediator. Unfortunately, the use of non-specific antioxidant scavengers in mouse and human studies has led to inconsistent results, obscuring our understanding of the importance of redox signaling in pathology of muscular dystrophy. However, recent studies with more mechanistic approaches in mdx mice suggest that NAD(P)H oxidase and nuclear factor-kappaB are important in amplifying dystrophin-deficient muscle pathology. Therefore, more targeted antioxidant therapeutics may ameliorate damage and weakness in human population, thus promoting better muscle function and quality of life. This review will focus upon the pathobiology of dystrophin deficiency in diaphragm and limb muscle primarily in mouse models, with a rationale for development of targeted therapeutic antioxidants in DMD patients.

Sarcopenia of ageing: functional, structural and biochemical alterations

Aging is associated with a progressive decline of muscle mass, strength, and quality, a condition described as sarcopenia of aging. Despite the significance of skeletal muscle atrophy, the mechanisms responsible for the deterioration of muscle performance are only partially understood. The purpose of this review is to highlight cellular, molecular and biochemical changes that contribute to age-related muscle weakness.

Murine models of atrophy, cachexia, and sarcopenia in skeletal muscle.

With the extension of life span over the past several decades, the age-related loss of muscle mass and strength that characterizes sarcopenia is becoming more evident and thus, has a more significant impact on society. To determine ways to intervene and delay, or even arrest the physical frailty and dependence that accompany sarcopenia, it is necessary to identify those biochemical pathways that define this process. Animal models that mimic one or more of the physiological pathways involved with this phenomenon are very beneficial in providing an understanding of the cellular processes at work in sarcopenia. The ability to influence pathways through genetic manipulation gives insight into cellular responses and their impact on the physical expression of sarcopenia. This review evaluates several murine models that have the potential to elucidate biochemical processes integral to sarcopenia. Identifying animal models that reflect sarcopenia or its component pathways will enable researchers to better understand those pathways that contribute to age-related skeletal muscle mass loss, and in turn, develop interventions that will prevent, retard, arrest, or reverse this phenomenon. This article is part of a Special Issue entitled: Animal Models of Disease.

Age-related decline in actomyosin structure and function

This review focuses on the role of changes in the contractile proteins actin and myosin in age-related deterioration of skeletal muscle function. Functional and structural changes in contractile proteins have been determined indirectly from specific force and unloaded shortening velocity of permeabilized muscle fibers, and were detected directly from site-directed spectroscopy in muscle fibers and from biochemical analysis of purified actin and myosin. Contractile proteins from aged and young muscle differ in (a) myosin and actomyosin ATPase activities, (b) structural states of myosin in contracting muscle, (c) the state of oxidative modifications. The extent of age-related physiological and molecular changes is dependent on the studied animal, the animals age, and the type of muscle. Therefore, understanding the aging process requires systematic, multidisciplinary studies on physiological, biochemical, structural, and chemical changes in specific muscles.

C57BL/6 Neuromuscular Healthspan Scoring System

Developing a scoring system based on physiological and functional measurements is critical to test the efficacy of potential interventions for sarcopenia and frailty in aging animal models; therefore, the aim of this study was to develop a neuromuscular healthspan scoring system (NMHSS). We examined three ages of male C57BL/6 mice: adults (6-7 months old, 100% survival), old (24-26 months old, 75% survival), and elderly group (>28 months old, ≤50% survival)-as well as mice along this age continuum. Functional performance (as determined by the rotarod and inverted-cling grip test) and in vitro muscle contractility were the determinants. A raw score was derived for each determinant, and the NMHSS was then derived as the sum of the individual determinant scores. In comparison with individual determinants, the NMHSS reduced the effect of individual variability within age groups, thus potentially providing an enhanced ability to detect treatment effects in future studies.

Myofibrillar myosin ATPase activity in hindlimb muscles from young and aged rats.

We tested the hypothesis that Ca(2+)-activated myosin ATPase activity is lower in muscles of aged rats relative to muscles of young rats, independent of changes in myosin isoform expression. Myofibrils were prepared from permeabilized fibers of soleus, plantaris, and semimembranosus muscles of young (8-12 months) and aged (32-38 months) F344 x BN rats and assayed for resting myosin ATPase, Ca(2+)-activated myosin ATPase, and myosin heavy chain (MHC) and myosin light chain (MLC) isoform compositions. Resting myosin ATPases were not affected by age in any muscle (P > or = 0.42). Ca(2+)-activated myosin ATPases of soleus and plantaris myofibrils were not affected by age (P > or = 0.31) but were 16% lower in semimembranosus myofibrils from aged rats (0.448 +/- 0.019 micromol P(i)/min/mg) compared to young rats (0.533 +/- 0.031 micromol P(i)/min/mg; P = 0.03). Correspondingly, maximal unloaded shortening velocity of single semimembranosus fibers from aged rats was slow (4.6 +/- 0.2 fiber lengths/s) compared with fibers from young rats (5.8 +/- 0.3 fiber lengths/s; P < 0.01). No age-related changes in MHC or regulatory MLC isoforms were detected in any muscle (P > or = 0.08) but changes in the essential MLC occurred in plantaris and semimembranosus muscles. The data indicate that Ca(2+)-activated myosin ATPase activity is reduced with age in semimembranosus muscle, independent of age-related changes in MHC isoform expression, and is one mechanism contributing to age-related slowing of contraction in that muscle.